These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 38601325

  • 1. Cataplexy response with extended-release once-nightly sodium oxybate: Post hoc responder analyses from the phase 3 REST-ON clinical trial.
    Thorpy MJ, Kushida CA, Bogan R, Ajayi AO, Corser BC, Gudeman J.
    Sleep Med X; 2024 Dec; 7():100109. PubMed ID: 38601325
    [Abstract] [Full Text] [Related]

  • 2. Weight Loss With Once-nightly Sodium Oxybate for the Treatment of Narcolepsy: Analysis From the Phase III Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium oxybate (REST-ON) Trial.
    Roth T, Morse AM, Bogan R, Roy A, Gudeman J, Dauvilliers Y.
    Clin Ther; 2024 Oct; 46(10):791-798. PubMed ID: 39153911
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial.
    Roth T, Dauvilliers Y, Thorpy MJ, Kushida C, Corser BC, Bogan R, Rosenberg R, Dubow J, Seiden D.
    CNS Drugs; 2022 Apr; 36(4):377-387. PubMed ID: 35380374
    [Abstract] [Full Text] [Related]

  • 5. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.
    Kushida CA, Shapiro CM, Roth T, Thorpy MJ, Corser BC, Ajayi AO, Rosenberg R, Roy A, Seiden D, Dubow J, Dauvilliers Y.
    Sleep; 2022 Jun 13; 45(6):. PubMed ID: 34358324
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial.
    Dauvilliers Y, Roth T, Bogan R, Thorpy MJ, Morse AM, Roy A, Dubow J, Gudeman J.
    Sleep; 2023 Nov 08; 46(11):. PubMed ID: 37246913
    [Abstract] [Full Text] [Related]

  • 7. Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary.
    Dauvilliers Y, Roth T, Bogan R, Thorpy MJ, Morse AM, Ascencion F, Gudeman J.
    J Comp Eff Res; 2024 Sep 08; 13(9):e240031. PubMed ID: 39088033
    [Abstract] [Full Text] [Related]

  • 8. Improvement in sleep latency with extended-release once-nightly sodium oxybate for the treatment of adults with narcolepsy: Analysis from the phase 3 REST-ON clinical trial.
    Thorpy MJ, Kushida CA, Bogan R, Winkelman J, Ohayon MM, Shapiro CM, Gudeman J.
    Sleep Med X; 2024 Dec 08; 7():100113. PubMed ID: 38774037
    [Abstract] [Full Text] [Related]

  • 9. Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary.
    Roth T, Thorpy MJ, Kushida CA, Horsnell M, Gudeman J.
    J Comp Eff Res; 2023 Dec 08; 12(12):e230133. PubMed ID: 37971303
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary.
    Rosenberg R, Braceras R, Macfadden W, Candler S, Black J, Ruoff C.
    Neurol Ther; 2023 Dec 08; 12(6):1805-1820. PubMed ID: 37755650
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers.
    Bogan R, Thorpy MJ, Winkelman JW, Dubow J, Gudeman J, Seiden D.
    Sleep Med; 2022 Dec 08; 100():442-447. PubMed ID: 36252412
    [Abstract] [Full Text] [Related]

  • 14. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis.
    Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS.
    J Clin Sleep Med; 2012 Aug 15; 8(4):451-8. PubMed ID: 22893778
    [Abstract] [Full Text] [Related]

  • 15. Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.
    Bogan RK, Foldvary-Schaefer N, Skowronski R, Chen A, Thorpy MJ.
    CNS Drugs; 2023 Apr 15; 37(4):323-335. PubMed ID: 36947322
    [Abstract] [Full Text] [Related]

  • 16. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.
    Black J, Swick T, Bogan R, Lai C, Carter LP.
    Sleep Med; 2016 Aug 15; 24():57-62. PubMed ID: 27810187
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.
    Lecendreux M, Plazzi G, Dauvilliers Y, Rosen CL, Ruoff C, Black J, Parvataneni R, Guinta D, Wang YG, Mignot E.
    J Clin Sleep Med; 2022 Sep 01; 18(9):2217-2227. PubMed ID: 35689598
    [Abstract] [Full Text] [Related]

  • 19. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.
    Bogan RK, Roth T, Schwartz J, Miloslavsky M.
    J Clin Sleep Med; 2015 Apr 15; 11(4):427-32. PubMed ID: 25580605
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.